Summit's Lung Cancer Drug: A Tale of Two Continents
Summit Therapeutics' promising lung cancer drug, ivonescimab, shows great results in China but struggles in Western trials, raising questions about its global future and impact on biotech.
NOTRELOAD AI
Dianthus Therapeutics: Myasthenia Gravis Drug Shows Promise
Dianthus's Claseprubart shows promising Phase 2 results for gMG, significantly improving daily activities & muscle strength with good safety. Plans for a convenient self-administered dose and a Phase 3 trial in 2026.
Rapport's RAP-219: Breakthrough for Focal Onset Seizures
RAP-219 shows amazing Phase 2a results for drug-resistant focal seizures: 77.8% seizure reduction & 24% seizure-free! This precision medicine, targeting TARPγ8, is well-tolerated & moves to Phase 3, offering new hope. Also eyed for bipolar mania & pain.
A New Dawn for Narcolepsy: Understanding Alixorexton's Promise
Alixorexton, a new drug for narcolepsy type 1, shows great promise. It helps patients stay awake longer (28 mins, considered normal), reduces sleepiness, cataplexy, fatigue, and improves focus. It's well-tolerated and moving to Phase 3, signaling a potential new era for treatment.
EchoStar Sells Spectrum to SpaceX for Next-Gen Starlink Direct-to-Cell
EchoStar sells its AWS-4 & H-block spectrum to SpaceX for ~$17B (cash/stock) & $2B debt interest. This powers SpaceX's next-gen Starlink Direct-to-Cell, aiming to end mobile dead zones worldwide. Boost Mobile will access the service.
Hesai LiDAR's Hong Kong Listing and Global Expansion
Lidar leader Hesai Group launches HK dual primary listing to raise up to US$500M. Offering 17M shares at max HK$228/share. Trading Sept 16. Funds for R&D, manufacturing, and expansion. Nasdaq ADSs remain fungible.